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 ^  60 years of age and older patients ( 1 60 years of age) 
showed a significant difference in genotype distribution
(p = 0.035); there was also an increased occurrence of risk al-
lele Pro72 in cases aged  ^  60 years (p = 0.045). A subset of
64 prostate tumors was stained immunohistochemically for 
P53. 5 of 64 prostate tumors (7.8%) were positive for P53 ex-
pression, indicating integrity of the protein in the majority of 
cases. Genotype distribution showed no association with 
the Gleason score or additional histopathological character-
istics. This study shows that the overall risk of prostate cancer 
was not associated with Arg72Pro SNP and HPV infection in 
our cohort. However, disease onset might be modulated by 
the p53 Pro72 allele, suggesting an important role of apop-
tosis regulation in prostate carcinogenesis. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Prostate cancer (PCa) is the most common cancer type 
in men and the 4th most common cancer type in Europe. 
Demographic development and the introduction of PSA 
screening will lead to an increasing incidence in the fu-
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 Abstract 
 The tumor suppressor gene p53 plays an important role in 
the stress response of the cell and is mutated in 50% of all 
human tumors. The p53 Arg72Pro single-nucleotide poly-
morphism (SNP) was found to be associated with an in-
creased risk of various malignancies. Biochemical and bio-
logical differences between the 2 polymorphic variants of 
wild-type P53 might lead to distinct susceptibility to HPV- 
and non-HPV-induced tumors. For prostate cancer, only
limited data are available, especially in the Caucasian pop-
ulation. Therefore, we determined the distribution of the
Arg72Pro SNP in a Caucasian case-control study including 
118 prostate cancer patients and 194 male controls without 
any malignancy using restriction fragment length polymor-
phism analysis. A subset of 33 tumors was tested for HPV 
 infection, and no HPV DNA was found. Cases and controls 
showed similar distributions of alleles in the SNP (p = 0.720). 
Regarding the onset of the disease, patients diagnosed at 
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ture. In 2008, there were 382,300 new PCa cases and 
89,300 cases of PCa-related deaths (9.3% of all cancer-
related causes of death in men) reported in Europe  [1] . 
PCa has a 5-year survival rate of 87% but often leads to 
severe restriction of men’s life quality and high expenses 
for the health care system  [2] . Therefore, the search for 
inherited cancer susceptibility factors, such as single-nu-
cleotide polymorphisms (SNPs), is a major focus of epi-
demiologic cancer studies. Analyses of SNPs in a variety 
of genes have revealed a correlation between specific al-
lele variants and cancer predisposition.
 The tumor suppressor gene p53 plays an important 
role in the stress response of the cell. In unstressed cells 
only low levels of P53 are present. P53 is ubiquitinated via 
MDM2 and ARF-BP1, which leads to degradation in the 
proteasome. In cases of cellular stress, like DNA damage, 
hypoxia, or oncogene activation, for example, the p53 
pathway is upregulated (via p21, PUMA, and BAX, among 
others) and this results in cellular stress responses such 
as apoptosis and DNA repair or cell cycle and growth
arrest  [3] . p53 is mutated in 50% of all human tumors, 
whereas 90% of those mutations lead to a decreased abil-
ity to bind DNA targets and hence to disability of appro-
priate stress-responses  [4, 5] . Mutations and other altera-
tions in p53 lead to increased proliferation, cell growth, 
and incomplete DNA-repair, which finally results in de-
velopment of malignancies. For PCa very discrepant fre-
quencies for p53 mutations are reported, ranging from 3 
to 42%. Among other reasons, this might be due to con-
siderable methodological heterogeneity  [6] .
 A well-studied single base pair variant of p53 in exon 
4, codon 72 represents a genomic polymorphism and not 
a mutation. This p53 Arg72Pro SNP encodes for 2 wild-
type variants of P53, either arginine (Arg72) or proline 
(Pro72). A single-base exchange from CGC to CCC causes 
the alteration of amino acid residue 72  [7] . Both wild-type 
forms have the same ability to bind DNA, but they show 
different potentials to bind components of the transcrip-
tional machinery, activate transcription, induce apopto-
sis, and repress the malignant transformation of cells  [8] . 
The Arg72 form induces apoptosis markedly better due to 
enhanced mitochondrial trafficking of this isoform  [9] .
 The association between the p53 codon 72 polymor-
phism and tumor formation has been extensively studied 
in various malignancies  [10] . In addition, the 2 polymor-
phic variants might lead to a different susceptibility to 
tumor induction by human papillomavirus (HPV). In 
non-HPV-induced tumors, Pro72 is assumed to be the 
risk allele for the development of cancer. However, in 
HPV-induced malignancies, the Arg72 especially leads to 
tumor formation as the oncogenic HPV E6 protein pref-
erentially targets Arg72 for ubiquitination-mediated deg-
radation  [11, 12] .
 For PCa only limited data are available about the as-
sociation between the p53 Arg72Pro polymorphism, 
HPV infection, and tumor growth, especially in the Cau-
casian population. Generally, only 2 studies showed a sig-
nificant association between this SNP and PCa risk, but 
they had conflicting results. While Henner et al.  [13] re-
ported a reduced PCa risk of the Pro72 variant in Cauca-
sians, Wu et al.  [14] found an increased risk for the devel-
opment of metastasis in Taiwanese PCa patients for the 
Pro72 isoform  [15] . However, in the Caucasian study, the 
distribution of genotypes for the control group was not 
consistent with Hardy-Weinberg equilibrium. 
 Due to these controversial results and a lack of reliable 
data about the genotype distribution in this p53 SNP in 
the Caucasian population, we analyzed the distribution 
of the Arg72Pro SNP in Caucasian PCa patients and in a 
healthy control group. Because of the possible association 
between HPV infection and an increased tumor risk 
modulated by the p53 Arg72Pro SNP, we also determined 
the HPV status in a subset of the tumors. 
 Subjects and Methods 
 Samples 
 Overall, 118 PCa patients, all of whom underwent radical pros-
tatectomy, were included in our study. Formalin-fixed and paraf-
fin-embedded tissue samples from these patients were available 
from the prostatectomy specimens. For comparison, 194 blood 
samples from a male control group of patients without any malig-
nancy were investigated.
 All tumors were diagnosed according to the 2004 WHO clas-
sification of prostate tumors  [16] and staged according the TNM 
system  [17] . The clinicopathological characteristics of the study 
participants are shown in  table 1 . IRB approval was obtained for 
this study.
 Tissue Microdissection and DNA Isolation 
 DNA was extracted from manually microdissected normal 
prostate tissue or peripheral blood using a High Pure PCR Tem-
plate Preparation Kit (Roche GmbH, Mannheim, Germany) ac-
cording to manufacturer’s instructions.
 P53 Arg72Pro SNP Analysis 
 SNP analysis was carried out by restriction fragment length 
polymorphism analysis (RFLP) of the polymorphic region in 
exon 4 which contains a  Bst  UI  recognition site (5  -CG f CG-3  ) 
in the presence of the G-allele (Arg72)  [18] . The presence of the 
Arg72 allele resulted in digestion of the PCR product (196 bp = 
113 + 83 bp), whereas PCR products containing the C-allele 
(Pro72) remained unaffected.
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 Amplification of Region Variants and RFLP Analysis 
 The SNP region was amplified by PCR using primers (sense: 
5  -TTG CCG TCC CAA GCA ATG-3  ; antisense: 5  -GGG AAG 
GGA CAG AAG ATG-3  ) obtained from Metabion (Martinsried, 
Germany) in a total volume of 25   l containing approximately 
100 ng DNA, 0.2 m M dNTP (Promega, Mannheim, Germany), 
0.18   M primers, and 0.0025 U/  l GoTaq (Promega). The thermal 
cycling conditions were as follows: initial denaturation for 3 min 
at 95  °  C, 35 cycles of denaturation at 95  °  C for 1 min, annealing at 
61   °   C for 1 min, elongation at 72   °   C for 1 min, and final primer 
extension at 72  °  C for 10 min. Gradient PCR was used for optimi-
zation of the cycling conditions.
 PCR products were incubated for 6 h with 5 U  Bst  UI (New 
England Biolabs, Frankfurt/Main, Germany) at 60   °   C in a total 
volume of 30   l to ensure complete digestion. Restriction frag-
ments were separated by electrophoresis using 2% agarose gels 
and visualized under ultraviolet light using 0.05% ethidium bro-
mide.
 Sequencing Analysis 
 Twelve randomly selected cases were sequenced to verify the 
RFLP results. After amplification, PCR products were purified 
using a Qiagene Dye Ex 2.0 TM Spin Kit according to the manu-
facturer’s instructions. Sequence analysis was performed with the 
primers mentioned above using an Applied Biosystems Big Dye 
Terminator v1.1 Cycle Sequencing Kit and an Applied Biosystems 
ABI PRISM 310 Genetic Analyzer.
 HPV PCR Analysis of Prostate Tumors 
 Tumor cells were microdissected and DNA was extracted us-
ing a High Pure PCR Template Preparation Kit (Roche) according 
to the manufacturer’s instructions. HPV DNA testing was per-
formed by PCR as described by Petry et al.  [19] .
 P53 Immunohistochemistry 
 Archival formalin-fixed, paraffin-embedded prostate tumors 
from 64 cases were assembled for tissue microarray (TMA). 
Three-micrometer sections were stained overnight with a P53 
mouse monoclonal antibody (clone DO-7, dilution 1: 50 with al-
bumin; DakoCytomation, Hamburg, Germany). P53 staining was 
detected using a ZytoChem Fast AP One-Step Polymer Kit 
(Zytomed Sytems, Berlin, Germany) according to the manufac-
turer’s instructions. As a positive control, a human peritoneal car-
cinosis specimen was stained in parallel to the TMA sections. Im-
munohistochemical staining was evaluated by an experienced 
surgical pathologist (A.H.) in a blinded fashion. Tumors with 
more than 10% nuclear staining for P53 were scored as positive.
 Statistical Analysis 
 To test if the genotype distribution followed Hardy-Weinberg 
equilibrium, the public software at http://ihg.gsf.de/cgi-bin/hw/
hwa1.pl was used.   2 statistics (2-sided exact significance) were 
used to evaluate case-control differences in the distribution of 
genotypes and to analyze associations between genotypes and age 
or histopathological characteristics. To determine the distribu-
tion of the risk allele versus the nonrisk allele, Fisher’s exact test 
(2-sided exact significance) was used. p  ! 0.05 was considered 
statistically significant.
 Results 
 Verification of the RFLP analysis by sequencing 
showed 100% concordance between the 2 methods. All 
results derived from the RFLP analysis could be con-
firmed by sequencing. Representative examples of geno-
typing are shown in  figure 1 , and representative sequenc-
ing results are shown in  figure 2 .
 The genotype distribution in our cohorts followed 
Hardy-Weinberg equilibrium in cases (p = 0.641) and 
controls (p = 0.575). The genotype distribution between 
cases and controls did not differ significantly (p = 0.720) 
( table 2 ;  fig. 3 ). There was also no correlation between the 
SNP distribution and the Gleason score (p = 0.718;  ta-
ble 2 ) or stage (p = 0.160;  table 2 ) of the tumors. 
 To analyze a possible age-dependent distribution of 
the p53 Arg72Pro SNP, we divided PCa cases into 2 
groups: one group consisted of younger patients ( ^  60 
years) and the second group consisted of patients with an 
age of  1 60 years at disease onset. Regarding the onset of 
the disease, there was a significant difference in genotype 
distribution between both groups (p = 0.035), with an in-
creased occurrence of the risk allele Pro72 in the younger 
patient group (p = 0.045) ( table 2 ;  fig. 4 a, b). This age-
dependent distribution was not detectable in the control 
group (p = 0.715). All results of the distribution of allelic 
variants between cases and controls and between relevant 
tumor/patient characteristics are shown in  table 2 .
Table 1. C haracteristics of study participants
Cases (n =118) Controls (n = 194)
Age, years
Median 65 69
Mean 8 years of age 64.286.0 67.3810.6
Range 46474 34488
Stage
Organ-confined 57
Non-organ-confined 55
No data available 6
Gleason score
Median 7
Range 3410
Gleason sum
3–4 3
5–7 84
8–10 22
No data available 9
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 To determine the integrity of the P53 protein in the 
tumors, a subset of 64 tumor specimens were analyzed 
immunohistochemically. Only 5/64 (7.8%) cases showed 
positivity for P53, indicating an altered p53 protein in 
only a small number of cases. Representative examples of 
P53 immunohistochemistry are shown in  figure 5 .
 For 33 tumor samples, sufficient amounts of tumor 
tissue could be obtained by microdissection to isolate 
DNA for HPV PCR. All 33 HPV-tested PCa specimens 
were found to be negative for HPV DNA by a PCR proto-
col covering a wide variety of HPV types, including the 
relevant high-risk and low-risk oncogenic HPV types. 
 Discussion 
 The tumor suppressor gene p53 plays a major role in 
the development of human malignancies. The polymor-
phic variant of p53 at codon 72 has been found to be as-
sociated with cancer susceptibility in various tumor enti-
ties, but only few studies have investigated its effect on 
PCa risk  [11] .
 In our study with 118 Caucasian PCa cases and 194 
healthy controls we found that the overall risk of PCa was 
not associated with the p53 Arg72Pro polymorphism. To 
date, only 3 studies have reported a statistically signifi-
cant association between genotype distribution and dis-
ease risk for PCa: one study in a Taiwanese cohort  [14] , a 
second study in a Caucasian cohort  [13] , and a third study 
in a patient cohort of individuals of African descent  [20] . 
However, all 3 studies showed controversial results and 
the Caucasian control group was not consistent with Har-
dy-Weinberg equilibrium, advising caution in the inter-
pretation of these results. Our study showed no associa-
tion between the p53 codon 72 SNP and PCa risk in a 
German PCa cohort, which is in line with 3 other non-
a b c
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 Fig. 1. Representative example for P53 
 Arg72Pro SNP RFLP analysis. Lanes 1 and 
18 = DNA standard; lanes 2–13 = samples; 
lane 14 = positive control; lane 16 = water 
control; lanes 15 and 17 = empty. 
 Fig. 2. Representative sequencing results 
for verification of the RFLP analysis. There 
was a 100% concordance between both 
methods.  a Homozygous Pro72, RFLP 
lane 2.  b Heterozygous variant, RFLP lane 
5.  c Homozygous Arg72, RFLP lane 7. 
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 Fig. 3. Graphic illustration of the distribution of p53 Arg72Pro 
SNP genotypes between controls and cases. No significant differ-
ence was found (p = 0.720). 
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Caucasian studies  [21–23] . To ensure that our control co-
hort was representative of Caucasians in terms of the ge-
notype distribution pattern, we compared our data with 
2 other Caucasian male control groups  [24, 25] and found 
very similar results (data not shown), strengthening the 
validity of our control group and of our results.
 However, our results provide evidence that disease on-
set might be modulated by the Pro72 allele. In our PCa 
cohort, patients aged  ^  60 years at the time of diagnosis 
showed a significant increase in the risk allele, suggesting 
the Pro72 variant as an inherited risk factor for earlier 
disease onset. This age-dependent shifting of the allele 
distribution was not seen in the control group. There is 
an ongoing discussion about the definition of early-onset 
PCa  [26] . The age mostly used for the definition of early 
disease onset in the literature ranges from 55 to 65 years 
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 Fig. 4. Age-dependent distribution of Arg72Pro SNP in tumor patients.  a A significant difference was found 
between patients aged  1 60 or  ^  60 years (p = 0.035);  b younger patients showed increased incidences of the 
Pro72 risk allele (p = 0.045). 
a b
 Fig. 5. Representative examples for positive and negative P53 immunohistochemistry.  a  PCa specimen [pT3a, 
G3, Gleason score 7 (4 + 3), with 15% of the cells showing nuclear staining]. Magnification  ! 400.  b Prostate 
tumor [pT3b, G2, Gleason score 6 (4 + 2) negative for P53]. Magnification  ! 400. 
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 [27, 28] ; for sporadic cancer the age at diagnosis is nor-
mally used equivalently to disease onset, which might 
imply a little bias. Due to a relatively low number of cases 
 ! 55 years of age at time of diagnosis in our unselected 
patient cohort, we chose the mean value of the age range 
widely used in the literature as the cut off for our analysis. 
Nevertheless, a larger cohort of patients with early dis-
ease onset (e.g.  ! 50 years) should be investigated to veri-
fy our results showing an age-dependent genotype distri-
bution of this polymorphism.
 Our results suggest that aberrant apoptosis regulation 
might play an important role in prostate carcinogenesis 
in younger patients. Indeed, PCa cells are able to develop 
various strategies to block apoptosis during progression 
from normal epithelial cells to PCa  [29] . The malignant 
transformation of prostatic cells is favored by disruption 
of the balance between the proliferation and apoptosis of 
prostatic epithelial cells, and P53 is an important factor 
in maintaining this balance  [30] . The molecular princi-
ples of impaired apoptosis by the Pro72 variant are still 
not fully understood. Recently, it was shown that there 
are different levels of transcription of P53-regulated genes 
by the p53 codon 72 SNP  [31] . Interestingly, most of the 
genes involved in apoptosis which were found to be dif-
ferentially expressed depending on the p53 variant were 
expressed at much lower levels in cells with the Pro72 
variant compared to the Arg72 isoform. With a constant 
lower expression of members of the apoptosis pathway in 
Table 2.  Distribution of allelic variants between cases and controls and between relevant tumor/patient charac-
teristics
Genotype Cases Controls C omparison
p OR 95% CI
Arg 65 (55.1) 104 (53.6)
Hetero 44 (37.3) 79 (40.7) 0.720
Pro 9 (7.6) 11 (5.7)
Arg 65 (55.1) 104 (53.6) 0.816 0.942 0.595–1.492
Hetero + Pro 53 (44.9) 90 (46.4)    
Cases Gleason sum <7 Cases Gleason sum ≥7
Arg 30 (61.2) 32 (53.3)
Hetero 16 (32.7) 23 (38.3) 0.718
Pro 3 (6.1) 5 (8.3)   
Arg 30 (61.2) 32 (53.3) 0.442 1.382 0.642–2.973
Hetero + Pro 19 (38.8) 28 (46.6)   
Organ-confined tumors Non-organ-confined tumors
Arg 31 (54.4) 33 (60)
Hetero 24 (41.2) 16 (29.1) 0.160
Pro 2 (3.5) 6 (10.9)
Arg 31 (54.4) 33 (60) 0.572 0.795 0.375–1.683
Hetero + Pro 26 (45.6) 22 (40)
Cases aged ≤60 Cases aged >60
Arg 10 (37) 51 (60.7)
Hetero 16 (59.3) 26 (31) 0.035
Pro 1 (3.7) 7 (8.3)   
Arg 10 (37) 51 (60.7) 0.045 0.381 0.155–0.932
Hetero + Pro 17 (63) 33 (39.3)   
Res ults are patient numbers with percentages in parentheses.
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cells with the P53 Pro72 variant, one might speculate that 
there is a higher susceptibility to an inadequate apoptot-
ic response to cellular damage and an earlier onset of a 
malignancy could be explainable.
 To further stress the possible importance of the p53 co-
don 72 SNP in PCa, we wanted to get some information on 
the integrity of the protein. Immunohistochemical staining 
revealed a low rate (7.8%) of P53 nuclear accumulation in 
the tumors, which indicated a minor role of P53 alterations 
in our cohort. This is in line with several previously pub-
lished studies  [32–34] . The high number of P53-negative 
tumors, hence, strengthens the plausibility of investigating 
SNPs in p53 as predictive and progressive markers in PCa.
 HPV infection is discussed controversially as a risk 
factor for PCa. Reported frequencies of HPV infections 
in PCa patients vary from 2 to 54%  [35] . Because of the 
known increased cancer risk for the combination of HPV 
infection and the homozygous Arg72 genotype in several 
malignancies, we also analyzed tumor tissue of a subset 
of our PCa cohort for HPV DNA. We could not find HPV 
DNA in these tumors, suggesting that HPV infection 
plays no major role in prostate carcinogenesis; this is in 
line with previously published studies  [36, 37] .
 In summary, our case-control study revealed no evi-
dence of an association between the P53 Arg72Pro poly-
morphism and an increased overall risk for PCa or of an 
association between this polymorphism and histopatho-
logical characteristics of the tumor. However, our results 
raise the possibility that the Pro72 variant is an inherited 
susceptibility marker for early disease onset in PCa. 
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